Diseases & Conditions Market Research Reports & Industry Analysis
Insomnia is a common condition in which one has trouble going to sleep or staying asleep. This condition can range from weak to strong, depending on how often it occurs and for how long. Insomnia can be ongoing or acute. Chronic insomnia means having symptoms at least 3 nights a week for more than a month. Acute insomnia lasts for less time. Some people who have insomnia will have trouble falling asleep. Other people may fall asleep easily but, then wake up.
Diseases & Conditions Industry Research & Market Reports
-
Genomics in Cancer Care
... 2030, growing at a CAGR of 16.7% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$25.0 Billion by the end ... Read More
-
Frozen Food
... CAGR of 6.5% over the analysis period 2024-2030. Raw Material, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$195.4 Billion by the end of the analysis ... Read More
-
Epilepsy Drugs
... CAGR of 3.8% over the analysis period 2024-2030. First Generation, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$1.6 Billion by the end of the analysis ... Read More
-
Doxorubicin
... 5.8% over the analysis period 2024-2030. Breast Cancer, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$374.1 Million by the end of the analysis period. Growth ... Read More
-
Breast Cancer Liquid Biopsy
... 2030, growing at a CAGR of 21.9% over the analysis period 2024-2030. Reagent Kits, one of the segments analyzed in the report, is expected to record a 22.4% CAGR and reach US$819.3 Million by the ... Read More
-
Books
... 2.9% over the analysis period 2024-2030. Mystery, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$35.4 Billion by the end of the analysis period. Growth in ... Read More
-
Parkinson’s Disease Drugs
... at a CAGR of 6.5% over the analysis period 2024-2030. Oral, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$4.6 Billion by the end of the ... Read More
-
Diabetes Diagnostics
... CAGR of 8.5% over the analysis period 2024-2030. Test Strips, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$14.7 Billion by the end of the analysis ... Read More
-
Microwave Ablation
... CAGR of 13.2% over the analysis period 2024-2030. Liver Cancer, one of the segments analyzed in the report, is expected to record a 15.2% CAGR and reach US$215.5 Million by the end of the analysis ... Read More
-
Rare Hematology
... CAGR of 4.9% over the analysis period 2024-2030. Plasma Derived Factors, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$18.2 Billion by the end of the ... Read More
-
Radiofrequency Ablation Devices for Pain Management
... reach US$1.4 Billion by 2030, growing at a CAGR of 9.9% over the analysis period 2024-2030. Disposable Products, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach ... Read More
-
Polycaprolactone
... 8.3% over the analysis period 2024-2030. Coating & Thermoplastic polyurethane (TPU), one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$141.2 Million by the end of the ... Read More
-
Zika Virus Testing
... at a CAGR of 5.8% over the analysis period 2024-2030. Molecular Testing, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$192.4 Million by the end of ... Read More
-
Wi-Fi Hotspot
... CAGR of 17.0% over the analysis period 2024-2030. Hardware, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$8.5 Billion by the end of the analysis period. ... Read More
-
Viral Hepatitis and Retrovirus Diagnostic Tests
... reach US$7.7 Billion by 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 11.3% CAGR The Viral ... Read More
-
Systemic Psoriasis Therapeutics
... at a CAGR of 8.1% over the analysis period 2024-2030. TNF Inhibitors, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$18.5 Billion by the end of ... Read More
-
Protein Supplements
... CAGR of 6.3% over the analysis period 2024-2030. Animal-Based, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$22.5 Billion by the end of the analysis period. ... Read More
-
Post-Traumatic Stress Disorder (PTSD) Therapeutics
... Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.1 Billion by ... Read More
-
Patient Derived Xenograft / PDX Models
... reach US$1.0 Billion by 2030, growing at a CAGR of 14.3% over the analysis period 2024-2030. Mice PDX Models, one of the segments analyzed in the report, is expected to record a 14.9% CAGR and ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
Nanosensors
... 58.6% over the analysis period 2024-2030. Healthcare, one of the segments analyzed in the report, is expected to record a 61.3% CAGR and reach US$14.1 Billion by the end of the analysis period. Growth in ... Read More
-
Meta Xylene
... CAGR of 4.7% over the analysis period 2024-2030. Isophthalic Acid Production, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$1.5 Billion by the end of the ... Read More
-
Malaria Diagnostics
... CAGR of 5.6% over the analysis period 2024-2030. Rapid Diagnostic Tests, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$685.9 Million by the end of the ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
-
Intrathecal Pumps
... CAGR of 5.1% over the analysis period 2024-2030. Morphine, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$115.9 Million by the end of the analysis period. ... Read More
Research Assistance
